Triamterene

Nephrotic Syndrome, Edema, Swollen feet or ankles + 8 more
Treatment
20 Active Studies for Triamterene

What is Triamterene

TriamtereneThe Generic name of this drug
Treatment SummaryTriamterene is a medication used to treat high blood pressure. It helps the body get rid of extra sodium and water while also preserving potassium. Taking this medication can increase the risk of high potassium levels in the blood, called hyperkalemia. Triamterene was approved by the FDA in 1964 and is used alone or in combination with other diuretics to enhance its effects. It is also found in a combination product with hydrochlorothiazide to treat high blood pressure or edema in people who become low on potassium when taking hydrochlorothiazide by itself.
Maxzideis the brand name
image of different drug pills on a surface
Triamterene Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Maxzide
Triamterene
1988
188

Effectiveness

How Triamterene Affects PatientsTriamterene is a drug used to treat high blood pressure and swelling. It works by blocking the body from absorbing too much salt and preventing the loss of potassium in the urine. This can lead to high levels of potassium in the blood (hyperkalemia), which can cause an irregular heartbeat. Triamterene also affects the kidney's ability to filter out other substances like sodium, magnesium, uric acid, and creatinine. It does not affect calcium excretion. When used with hydrochlorothiazide, it has been found to lower blood pressure even further.
How Triamterene works in the bodyTriamterene works on the kidneys to stop the body from absorbing too much sodium, which increases urine production. It blocks certain proteins called epithelial sodium channels from absorbing sodium ions from the peritubular medium and forces them out of the cells, leading to increased excretion of sodium, water, potassium, hydrogen, and chloride ions in the urine. Triamterene also increases the excretion of magnesium, unlike amiloride. Its action helps balance the levels of electrolytes in the body.

When to interrupt dosage

The endorsed dosage of Triamterene is subject to the diagnosed condition, including Cirrhosis, Hypokalemia and Edema. The measure of dosage is contingent upon the method of administration (e.g. Capsule or Tablet - Oral) mentioned in the table below.
Condition
Dosage
Administration
Edema
, 75.0 mg, 37.5 mg, 50.0 mg, 100.0 mg
Oral, Tablet - Oral, Tablet, , Capsule - Oral, Capsule
Congestive Heart Failure
, 75.0 mg, 37.5 mg, 50.0 mg, 100.0 mg
Oral, Tablet - Oral, Tablet, , Capsule - Oral, Capsule
Edema
, 75.0 mg, 37.5 mg, 50.0 mg, 100.0 mg
Oral, Tablet - Oral, Tablet, , Capsule - Oral, Capsule
Edema
, 75.0 mg, 37.5 mg, 50.0 mg, 100.0 mg
Oral, Tablet - Oral, Tablet, , Capsule - Oral, Capsule
Thiazides
, 75.0 mg, 37.5 mg, 50.0 mg, 100.0 mg
Oral, Tablet - Oral, Tablet, , Capsule - Oral, Capsule
Hypokalemia
, 75.0 mg, 37.5 mg, 50.0 mg, 100.0 mg
Oral, Tablet - Oral, Tablet, , Capsule - Oral, Capsule
Nephrotic Syndrome
, 75.0 mg, 37.5 mg, 50.0 mg, 100.0 mg
Oral, Tablet - Oral, Tablet, , Capsule - Oral, Capsule
Swollen feet or ankles
, 75.0 mg, 37.5 mg, 50.0 mg, 100.0 mg
Oral, Tablet - Oral, Tablet, , Capsule - Oral, Capsule
Hypertensive disease
, 75.0 mg, 37.5 mg, 50.0 mg, 100.0 mg
Oral, Tablet - Oral, Tablet, , Capsule - Oral, Capsule
Diuretics
, 75.0 mg, 37.5 mg, 50.0 mg, 100.0 mg
Oral, Tablet - Oral, Tablet, , Capsule - Oral, Capsule
Cirrhosis
, 75.0 mg, 37.5 mg, 50.0 mg, 100.0 mg
Oral, Tablet - Oral, Tablet, , Capsule - Oral, Capsule

Warnings

Triamterene Contraindications
Condition
Risk Level
Notes
Renal Insufficiency, Chronic
Do Not Combine
Hyperkalemia
Do Not Combine
Pulse Frequency
Do Not Combine
Anuria
Do Not Combine
Liver diseases
Do Not Combine
There are 20 known major drug interactions with Triamterene.
Common Triamterene Drug Interactions
Drug Name
Risk Level
Description
Cyclosporine
Major
The risk or severity of hyperkalemia can be increased when Triamterene is combined with Cyclosporine.
Neomycin
Major
The risk or severity of nephrotoxicity can be increased when Triamterene is combined with Neomycin.
Tacrolimus
Major
The risk or severity of hyperkalemia can be increased when Triamterene is combined with Tacrolimus.
Tenofovir
Major
Triamterene may increase the nephrotoxic activities of Tenofovir.
Tenofovir alafenamide
Major
Triamterene may increase the nephrotoxic activities of Tenofovir alafenamide.
Triamterene Toxicity & Overdose RiskThe toxic dose of triamterene in rats is 400mg/kg and 285-380mg/kg in mice. There have been cases of reversible kidney failure from taking 50 pills containing 50mg triamterene and 25mg hydrochlorothiazide. Symptoms of overdose include nausea, vomiting, stomach pains, weakness, and low blood pressure due to changes in electrolyte levels. There is no specific antidote for triamterene overdose, so medical treatments such as vomiting and gastric lavage are used to remove the drug from the stomach. Dialysis may also be used to help reduce the effects of the overdose
image of a doctor in a lab doing drug, clinical research

Triamterene Novel Uses: Which Conditions Have a Clinical Trial Featuring Triamterene?

138 active trials are currently underway to assess the efficacy of Triamterene in providing relief from Cirrhosis, Hypokalemia and Nephrotic Syndrome.
Condition
Clinical Trials
Trial Phases
Cirrhosis
52 Actively Recruiting
Phase 1, Phase 2, Not Applicable, Phase 3, Phase 4, Early Phase 1
Edema
7 Actively Recruiting
Phase 4, Phase 2, Not Applicable, Phase 3
Diuretics
0 Actively Recruiting
Swollen feet or ankles
5 Actively Recruiting
Phase 2, Not Applicable, Phase 4
Congestive Heart Failure
11 Actively Recruiting
Not Applicable, Phase 1, Phase 2
Edema
0 Actively Recruiting
Hypertensive disease
27 Actively Recruiting
Not Applicable, Phase 1, Phase 2, Phase 3
Edema
0 Actively Recruiting
Hypokalemia
0 Actively Recruiting
Thiazides
0 Actively Recruiting
Nephrotic Syndrome
5 Actively Recruiting
Phase 2, Not Applicable, Phase 3

Triamterene Reviews: What are patients saying about Triamterene?

5Patient Review
5/20/2019
Triamterene for High Blood Pressure
This is by far the best medication I've ever been prescribed. It helped me lose 15 pounds and lower my blood pressure, all without any negative side effects that I can tell. It's a miracle drug, for sure.
4.7Patient Review
1/25/2018
Triamterene for High Blood Pressure
After taking this medication for two years, my blood pressure averaged 117/76. The side effects I experienced were morning dizziness, occasional dry mouth, and sometimes at bedtime. I decided to take the drug every other day instead of daily. After two months, there was no change. I tried eliminating the med entirely, and after three days my BP went up to 140/90. I resumed the drug 4 times per week. In two weeks I will test again and may have to resume a daily dose. Despite the minor side effects, I'll continue with a good diet and regular exercise.
4.3Patient Review
1/19/2018
Triamterene for Visible Water Retention
I had really bad leg cramps while trying to sleep; this made it impossible to get a good night's rest.
3.3Patient Review
9/30/2013
Triamterene for High Blood Pressure
I only experience ringing and a clogged feeling in my ears as side effects, but they are both incredibly annoying. I used to have very mild ringing but it has increased significantly since taking this drug regularly.
3Patient Review
2/26/2018
Triamterene for High Blood Pressure
After a week of taking this medication, I have felt lightheadedness, fogginess, and heart flutters. These effects have been persistent for two days now, but my breathing has also become labored at times. I don't feel that my blood pressure has lowered as intended. I have a doctor's appointment tomorrow to discuss these issues further and currently am dieting in hopes of dropping weight so that I can get off the medication entirely.
3Patient Review
6/11/2014
Triamterene for High Blood Pressure
My blood pressure did go down after taking this medication, but I experienced some pretty severe leg cramps, fatigue, and nausea. The worst side effect for me, though, was the canker sores that developed throughout my mouth.
3Patient Review
8/6/2013
Triamterene for Visible Water Retention
3Patient Review
1/30/2014
Triamterene for Visible Water Retention
This medication gave me heartburn, an upset stomach, and unfortunately caused weight gain.
3Patient Review
2/25/2014
Triamterene for High Blood Pressure
I experience tinnitus as a side effect of this medication.
2.7Patient Review
5/22/2013
Triamterene for High Blood Pressure
2.3Patient Review
2/7/2018
Triamterene for High Blood Pressure
I experienced some pretty intense and uncomfortable side effects while taking this medication. My urine had a loud, foul smell that I couldn't get rid of no matter what I did. In addition to that, I constantly felt congested and coughed as if I had a cold. It was hard to breathe properly. Thankfully, all my symptoms went away just 2 days after stopping the medicine.
2.3Patient Review
4/4/2014
Triamterene for High Blood Pressure
I would recommend keeping an eye on your sodium and potassium levels while taking this medication. I experienced some strange symptoms, including fainting, and it turns out that it was due to low sodium from taking triamterene for three years. Once I switched medications, my sodium levels were fine again.
2.3Patient Review
11/4/2017
Triamterene for High Blood Pressure
This medicine has been helpful in addressing the fluid retention that is a symptom of Meniere's Disease. However, I have found it makes me tired and exacerbates my dry eyes. Additionally, I've experienced more leg cramps since starting this medication.
2Patient Review
5/16/2022
Triamterene for Visible Water Retention
My doctor switched me to this medication from a diuretic combo that included this same drug because of my gout. I've been on it for almost a month now and I'm already retaining water again. All my joints hurt, especially my knees. Sometimes I get so lightheaded I feel like I'm going to pass out. This was supposed to be preventative against gout flares in the first place, but since being on it I've started having them again. Going to see about getting back on my old diuretic.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about triamterene

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is triamterene a good blood pressure medication?

"The conclusion of the study was that triamterene has the ability to lower blood pressure in addition to its potassium-sparing action."

Answered by AI

Is triamterene the same as hydrochlorothiazide?

"Hydrochlorothiazide and triamterene are both diuretics, which means they help prevent the body from absorbing too much salt. Hydrochlorothiazide is a thiazide diuretic, while triamterene is a potassium-sparing diuretic. Both of these drugs help keep the body's fluid levels balanced."

Answered by AI

What are the side effects of Triamterene HCTZ 37.5 25?

"You may experience:

stomach pain, nausea, diarrhea, or constipation;

dizziness, headache; or

blurred vision; or

dry mouth."

Answered by AI

What are the side effects of the medication triamterene?

"The following effects may occur: dizziness, lightheadedness, tiredness, headache, stomach upset, or diarrhea. If any of these effects last or get worse, tell your doctor or pharmacist. To reduce the risk of dizziness and lightheadedness, get up slowly when rising from a sitting or lying position."

Answered by AI

Clinical Trials for Triamterene

Image of U Health in Miami, United States.

Cuffless PPG Monitor for High Blood Pressure

18+
All Sexes
Miami, FL
This study aims to validate the accuracy and reliability of blood pressure (BP) estimates obtained over 24 hours using a PPG-based chest-patch device compared to the gold standard ambulatory blood pressure monitoring (ABPM) method using an upper arm cuff-based oscillometric BP device, in both hypertensive and normotensive individuals referred by their provider to undergo a 24-hours ABPM for clinical indication. The Awake/Asleep test, which is the primary test recommended for automated wearable cuffless BP devices that are cuff-calibrated (based on the 2023 European Society of Hypertension (ESH) recommendations for the validation of cuffless blood pressure measuring devices), will be conducted in this study. The secondary aim of the study is to assess the feasibility and convenience of the PPG-based device.
Waitlist Available
Has No Placebo
U Health (+1 Sites)Ziad Zoghby, M.D., M.B.A.Biobeat Technologies Ltd.
Image of Cedars-Sinai Medical Center in Los Angeles, United States.

AI-Enabled Identification for Fatty Liver Disease

18+
All Sexes
Los Angeles, CA
The goal of this prospective, multicenter, open-label, blinded end-point pragmatic study is to evaluate an artificial intelligence (AI)-augmented echocardiography screening approach for early detection of metabolic dysfunction associated steatotic liver disease (MASLD) and/or cirrhosis, in patients undergoing routine transthoracic echocardiograms (TTEs). The main question it aims to answer is to: 1. Evaluate notification responsiveness and rates of confirmatory testing for patients identified as high risk for having liver disease to determine whether optimized notifications increase timely confirmatory testing and treatment initiation versus standard of care assessment. 2. Compare time to diagnosis, treatment uptake, and clinical outcomes (hospitalizations, incident ASCVD, mortality) between cohorts identified as high risk by the AI algorithm and comparison groups to determine whether AI guided screening shortens time to diagnosis and increases appropriate treatment.
Waitlist Available
Has No Placebo
Cedars-Sinai Medical Center (+3 Sites)
Have you considered Triamterene clinical trials? We made a collection of clinical trials featuring Triamterene, we think they might fit your search criteria.Go to Trials
Image of University of Alabama at Birmingham in Birmingham, United States.

Dietary Interventions for Hypertension

18+
All Sexes
Birmingham, AL
Natriuretic peptides (NPs) are hormones produced by the heart and play an important role in maintaining cardiovascular health and have favorable metabolic benefits. Low NP levels are associated with an increased likelihood of the development of cardiometabolic diseases like diabetes and hypertension. NP levels are known to be highly heritable, with up to half of the differences in NP levels being explained by genetics. The investigators aim to describe the genetic architecture of NPs by examining the genetic variants associated with NPs, and generate and validate a polygenic score (PGS) for NPs. The investigators will use this NP PGS to examine the association of genetically determined NP levels with cardiometabolic and cardiovascular outcomes. The investigators will conduct a genotype-guided physiological clinical trial that aims to assess the genetic factors affecting NP levels and their impact on blood pressure and NP response to saline infusion, high-salt diet, and low-salt diet. These findings will help support personal medicine approaches to lower the increasing burden of hypertension in the United States.
Waitlist Available
Has No Placebo
University of Alabama at BirminghamPankaj Arora, MD, FAHA
Image of Cleveland Clinic Main Campus in Cleveland, United States.

Metabolic Surgery and TIPS for Liver Cirrhosis

18 - 70
All Sexes
Cleveland, OH
Cirrhosis is a form of advanced liver disease that can lead to serious complications, especially when combined with severe obesity. Many patients with cirrhosis also develop a condition called clinically significant portal hypertension (CSPH), which is increased pressure in the veins of the liver. CSPH raises the risk of life-threatening events like internal bleeding and liver failure. Unfortunately, treatment options for people who have both cirrhosis and severe obesity are very limited, especially when portal hypertension is present. This study, called the OPTIMAL Trial, is a randomized clinical trial designed to evaluate whether combining two procedures improves health outcomes in this high-risk population. The first procedure, called TIPS (Transjugular Intrahepatic Portosystemic Shunt), is a minimally invasive treatment that reduces pressure in the liver by creating a pathway for blood to flow more easily. The second procedure is sleeve gastrectomy, a form of metabolic (bariatric) surgery that helps patients lose weight and improve related conditions like diabetes. The study will compare two groups: 1. One group will receive TIPS followed by sleeve gastrectomy (TIPS+SG). 2. The other group will receive medical weight management (standard non-surgical care, including diet, lifestyle changes, and weight loss medications). All participants will have severe obesity and cirrhosis with CSPH but will not have decompensated liver disease (such as large amounts of fluid in the abdomen, a history of variceal bleeding, or recent liver failure). Eligible participants will be randomly assigned to one of the two groups. The main goal of the study is to determine whether the combination of TIPS + SG improves quality of life and leads to greater weight loss compared to medical therapy alone. The study will also monitor for any complications from either the procedures or the medical treatment. Participants will be followed for 6 months after their treatment starts, with periodic assessments of their physical health, liver function, and overall well-being. Some participants may also be followed for a longer period to assess long-term outcomes. This study hopes to provide high-quality evidence for a novel, stepwise treatment strategy that may help people with obesity and liver disease live longer, healthier lives. If successful, it could change how advanced liver disease and obesity are managed together, especially in patients who currently have few safe and effective options. All study care is provided at Cleveland Clinic, Cleveland, Ohio, USA.
Phase 4
Recruiting
Cleveland Clinic Main CampusSobia Laique, MD
Image of NewYork-Presbyterian/Weill Cornell Medical Center in New York, United States.

Melatonin for Liver Cirrhosis

18+
All Sexes
New York, NY
The goal of this clinical trial is to learn the affect of melatonin on sleep, cognitive function, and quality of life (QoL) in patients with cirrhosis and a complication called hepatic encephalopathy (HE). The main questions this study aims to answer are: * Does taking melatonin increase REM sleep, an important part of healthy sleep that is reduced in cirrhosis? * Does taking melatonin improve cognitive function and reported QoL? This is a pilot study, where participants will: * take one month of melatonin, followed by one month of thiamine, which is another supplement but is not suspected to impact sleep significantly. * Undergo cognitive testing and take surveys * Wear a commercial wearable sleep tracker * Have a formal sleep study and salivary melatonin collection at the end of taking each supplement at our sleep center Participants will be blinded, and neither they nor the researchers will know which supplement they are taking first and which they are taking second. They will also be randomized, with half starting with melatonin and the other half starting with thiamine.
Recruiting
Has No Placebo
NewYork-Presbyterian/Weill Cornell Medical CenterAdam Buckholz, MD MS
Have you considered Triamterene clinical trials? We made a collection of clinical trials featuring Triamterene, we think they might fit your search criteria.Go to Trials
Image of Virginia Commonwealth University in Richmond, United States.

Endovascular Treatment for Stroke

18+
All Sexes
Richmond, VA
Endovascular therapy (EVT) has proven to be more beneficial for patients with AIS caused by large vessel occlusions (LVO) than medical management alone. A recent meta-analysis of 5 RCTs showed that EVT significantly reduced disability at 90 days compared to medical management \[1\]. Despite its obvious benefits, patients may have neurological deterioration despite successful thrombectomy due to ischemia progression, intracranial hemorrhage, re-occlusion, or vasogenic edema. The incidence of early neurological deterioration (END) following EVT for acute stroke has been reported to be ranging from 14.1-35.2% with some studies defining END up to 7 days and some restricting the definition between 6-72 hours post thrombectomy. A small proportion of these patients, approximately 5.9-10.5%, experienced sICH following EVT. Whether END occurs due to ischemic or hemorrhagic it leads to worse outcomes.
Waitlist Available
Has No Placebo
Virginia Commonwealth UniversityAarti Sarwal
Image of Research Site in Calgary, Canada.

Baxdrostat for Hyperaldosteronism

18+
All Sexes
Calgary, Canada
This is a Phase III, multicentre, randomised, double-blind, placebo-controlled, parallel-group study to evaluate the safety, tolerability, and efficacy of baxdrostat versus placebo, on the reduction of Seated Blood Pressure (SBP) and unsuppression of Plasma Renin Activity (PRA) in approximately 180 participants ≥ 18 years of age with Primary Aldosteronism (PA), with or without prior treatment with Mineralocorticoid Receptor Antagonists (MRAs) or potassium-sparing diuretics. Baxdrostat (or placebo) will be administered once daily, up-titrated after 2 weeks to based on clinical response and tolerability. The study is planned to be conducted globally in approximately 90 study centres and approximately 12 countries.
Phase 3
Recruiting
Research Site (+22 Sites)AstraZeneca
Image of Future Life Clinical Trials in Miami, United States.

Extended vs Immediate Release Torsemide for Heart Failure

18+
All Sexes
Miami, FL
The primary objective of this study is to learn whether a morning dose of extended-release torsemide enhances renal sodium excretion after lunch (4-8 hours after dosing) compared to immediate-release torsemide. This is a randomized, double-blind, crossover study in patients with heart failure who are on a stable dose of a loop diuretic. During the study period, participants' current loop diuretics will be replaced with an equivalent dose of either immediate-release or extended-release torsemide. Following a one-week stabilization period on the assigned torsemide formulation, patients will report to the clinical site for an assessment visit. On the study day, patients will take a single dose of the same torsemide formulation they have been on for the past week, administered after breakfast. Urine samples be collected are: * 0-4 hours post-dosing (pre-lunch period) * 4-8 hours post-dosing (post-lunch period) * 8-24 hours post-dosing (24 hours period) The primary endpoint will be urinary sodium excretion (4-8 hours after dosing). This will be compared between the extended-release arm and the immediate-release arm to assess the efficacy of prolonged diuretic action. In addition, urinary potassium and creatinine excretion and creatinine clearance will be measured in all urine samples as the safety endpoints.
Phase 4
Recruiting
Future Life Clinical TrialsSalim Shah, PhD, JDSarfez Pharmaceuticals, Inc.
Have you considered Triamterene clinical trials? We made a collection of clinical trials featuring Triamterene, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security